The MDM2-p53 binding antagonists were developed to bind to MDM2 in the p53-binding pocket, allow p53 to accumulate, and then activate the p53 pathway in cancer cells, resulting in cell cycle arrest and apoptosis or senescence, depending on the cell type. Here, MDM2 is linked to cancer.